Stockwatch: an inauspicious start to earnings season
This article was originally published in Scrip
Executive Summary
The first-quarter 2015 earnings season actually started a couple of weeks ago with The Medicines Company's shock preannouncement that sales of its anticoagulant Angiomax (bivalirudin) would be about a share price-whopping third lower than expectations (scripintelligence.com, 10 April 2015). Hospital wholesalers had slowed their ordering of Angiomax ahead of an Appeal Court decision that could result in a generic bivalirudin being available in the US in a few months.